Cellebrite names Shiven Ramji CEO, replacing Thomas Hogan
CLBT•CEO transition announced
Cellebrite said Thomas E. Hogan stepped down as CEO effective Aug. 13, 2026, under a mutual agreement.
The company appointed Shiven Ramji as CEO as part of a planned succession.
Board resignation and adviser role
Hogan also resigned from the board on Aug. 13, 2026.
He will serve as an adviser for six months.
Related News
U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
BMY•
BridgeBio launches secondary offering of 5,000,000 shares by KKR Genetic Disorder LP
BBIO•
